Insmed’s Arikayce Scores Big Win in Phase 3 Study – Could Soon Treat Early-Stage MAC Lung Disease

Insmed announced positive topline results from the Phase 3b ENCORE study of Arikayce in newly diagnosed MAC lung disease. The drug showed statistically significant improvements in respiratory symptoms and culture conversion rates vs standard therapy.